Aprea Therapeutics, Inc. 8-K

What Happened
Aprea Therapeutics, Inc. announced via Form 8-K filed April 1, 2026 (Item 7.01, Regulation FD disclosure) that it has closed a previously announced private placement, generating approximately $30 million in gross proceeds. The company attached a press release about the closing as Exhibit 99.1 to the filing.

Key Details

• Filing date: April 1, 2026 (Form 8-K, Item 7.01).
• Gross proceeds from the private placement: approximately $30 million.
• Press release describing the closing is attached as Exhibit 99.1 to the 8-K.
• The 8-K was signed by Oren Gilad, Ph.D., President and CEO of Aprea Therapeutics.

Why It Matters
This transaction represents a capital raise that increases Aprea’s reported gross proceeds by roughly $30 million, which can affect the company’s liquidity and funding for its operations or programs. The 8-K furnishes the disclosure under Regulation FD and refers investors to the attached press release for additional details; investors should review that release and upcoming filings for information on securities issued, net proceeds, and intended use of funds.